GO:0072537 fibroblast activation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072537 (fibroblast activation) is defined as a change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand.
• Fibroblast activation is driven by mechanosignaling through YAP and TAZ, which translocate to the nucleus and induce pro-fibrotic gene programs.
• Key molecular mediators include FAP, STAT3, CCL2, PU.1/Spi1, GATA2, and the long non-coding RNA LINC01013, which encodes a fibroblast-activating micropeptide.
• Fibroblast activation is central to fibrosis in the heart, lung, kidney, and periodontal ligament, and it contributes to cancer-associated fibroblast immunosuppression in the tumor microenvironment.
• TGF-beta1 and FAP enzymatic activity are essential for fibroblastic differentiation of human periodontal ligament cells, linking soluble ligands to activation.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of fibroblast activation genes in disease-relevant contexts.
Description
Fibroblast activation (GO:0072537) is a biological process in which fibroblasts change their morphology or behavior in response to activating factors such as cellular or soluble ligands. This process is fundamental to wound healing, tissue remodeling, and the pathogenesis of fibrosis and cancer. Researchers study fibroblast activation because it represents a convergence point where mechanical cues, soluble cytokines, and transcriptional programs reshape the fibroblast phenotype. In the heart, signaling mechanisms regulating fibroblast activation, phenoconversion, and fibrosis have been reviewed as central to cardiac pathology. In the lung, mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis, establishing a direct link between mechanical force and transcriptional activation. In cancer, fibroblast activation protein (FAP) promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. These examples illustrate that fibroblast activation is not a single event but a coordinated program involving mechanotransduction, cytokine signaling, and epigenetic or non-coding RNA regulation. Understanding GO:0072537 therefore requires integrating cell biology, signal transduction, and disease models. The term is also relevant to regenerative biology, as resistance training rejuvenates aging skin by reducing circulating inflammatory factors and enhancing dermal extracellular matrices, a process in which fibroblast behavior is central. In dental biology, the enzymatic activity of fibroblast activation protein-alpha is essential for TGF-beta1-induced fibroblastic differentiation of human periodontal ligament cells. Collectively, these studies position fibroblast activation as a tractable and medically important process for CRISPR-based functional genomics.
fibroblast activation At A Glance
| GO ID | GO:0072537 |
|---|---|
| GO term | fibroblast activation |
| Ontology | biological_process |
| Synonym | none |
| Definition | A change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand. |
| Major function | Conversion of resting fibroblasts to an activated phenotype with altered morphology, contractility, proliferation, migration, and secretory activity. |
| Key activating factors | Soluble ligands such as TGF-beta1 and cellular ligands; mechanical cues transduced by YAP/TAZ. |
| Representative mediators | FAP, STAT3, CCL2, PU.1/Spi1, GATA2, LINC01013-encoded micropeptide. |
| Disease relevance | Fibrosis in heart, lung, kidney, and periodontal ligament; cancer-associated fibroblast immunosuppression. |
What Is GO:0072537?
According to the Gene Ontology, fibroblast activation (GO:0072537) is a change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand. In practical terms, this definition covers the transition of a resting fibroblast toward an activated state characterized by altered shape, increased contractility, proliferation, migration, and secretion of extracellular matrix components and cytokines. The activating factor can be a soluble ligand such as TGF-beta1 or a cellular ligand presented in the tissue microenvironment. The definition is deliberately broad because activation can be triggered by diverse stimuli, including mechanical signals transduced through YAP and TAZ. The process is distinct from fibroblast differentiation or fibrosis per se, although activation is often a prerequisite for these outcomes. Researchers use GO:0072537 to annotate experiments in which fibroblasts are exposed to defined activating factors and subsequently display measurable changes in morphology or behavior.
Why Is fibroblast activation Important in Cell Biology?
Fibroblast activation is important because it sits at the intersection of normal tissue repair and pathological fibrosis, and it is a major determinant of outcomes in cancer, cardiovascular disease, kidney injury, and dental pathology. Because the process is triggered by defined activating factors, it is experimentally tractable: researchers can expose fibroblasts to ligands or mechanical stimuli and measure activation markers, making GO:0072537 a useful annotation target for functional genomics. The identification of non-coding regulators such as LINC01013 and its encoded micropeptide further expands the regulatory landscape of fibroblast activation, suggesting new therapeutic entry points. In cancer, FAP-positive cancer-associated fibroblasts promote immunosuppression through STAT3-CCL2 signaling, linking fibroblast activation directly to immune evasion. In acute kidney injury, PU.1/Spi1 exacerbates ischemia-reperfusion injury by upregulating Gata2 and promoting fibroblast activation, demonstrating that transcriptional regulators can drive the process in vivo. Finally, interventions that reduce circulating inflammatory factors and enhance dermal extracellular matrices, such as resistance training, highlight the potential to modulate fibroblast behavior for tissue rejuvenation.
• Fibroblast activation is a core mechanism of tissue fibrosis in the heart, lung, kidney, and periodontal ligament.
• Mechanosignaling through YAP and TAZ directly couples mechanical cues to fibroblast activation and fibrosis.
• FAP-positive cancer-associated fibroblasts promote immunosuppression via STAT3-CCL2 signaling in the tumor microenvironment.
• PU.1/Spi1 drives fibroblast activation in ischemia-reperfusion acute kidney injury by upregulating Gata2.
• LINC01013 is a determinant of fibroblast activation and encodes a novel fibroblast-activating micropeptide.
• TGF-beta1-induced fibroblastic differentiation of human periodontal ligament cells requires FAP enzymatic activity.
• Fibroblast behavior contributes to dermal extracellular matrix remodeling and skin rejuvenation in response to resistance training.
• Fibroblast activation is a prerequisite for phenoconversion and fibrosis in cardiac tissue.
• The process is experimentally inducible with defined soluble or cellular ligands, enabling reproducible assays.
• CRISPR functional genomics can causally test candidate regulators of fibroblast activation in disease models.
What Happens During fibroblast activation?
Exposure to activating factors
In simple terms: A resting fibroblast first encounters a signal that tells it to wake up and change.
Fibroblast activation begins when a fibroblast is exposed to an activating factor such as a cellular or soluble ligand, as specified in the GO:0072537 definition. Soluble ligands include TGF-beta1, which induces fibroblastic differentiation of human periodontal ligament cells in a manner dependent on fibroblast activation protein-alpha enzymatic activity. Cellular ligands and mechanical cues can also serve as activating factors; mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis, showing that physical forces are converted into biochemical signals. The nature of the activating factor determines the downstream signaling route, but the common outcome is a change in fibroblast morphology or behavior.
Mechanotransduction and YAP/TAZ nuclear translocation
In simple terms: Physical forces are converted into gene-regulating signals inside the cell.
Mechanosignaling through YAP and TAZ is a well-established driver of fibroblast activation and fibrosis. When fibroblasts experience altered mechanical tension, YAP and TAZ translocate to the nucleus and cooperate with transcriptional partners to induce pro-fibrotic gene programs. This step links the physical microenvironment to the morphological and behavioral changes that define GO:0072537. Because YAP/TAZ activity is responsive to cytoskeletal tension, this mechanism provides a feedback loop in which activated fibroblasts remodel matrix and further reinforce activation.
Cytokine and transcriptional amplification
In simple terms: Activated fibroblasts release signals that recruit more cells and strengthen the response.
Once activated, fibroblasts can secrete cytokines and chemokines that amplify the response. In the tumor microenvironment, FAP promotes immunosuppression by cancer-associated fibroblasts via STAT3-CCL2 signaling, demonstrating that fibroblast activation can reshape immune cell recruitment. Transcriptional regulators also drive activation in vivo; PU.1/Spi1 exacerbates ischemia-reperfusion induced acute kidney injury via upregulating Gata2 and promoting fibroblast activation. These examples show that fibroblast activation is not a passive response but an actively amplified program involving STAT3, CCL2, PU.1/Spi1, and GATA2.
Non-coding RNA and micropeptide control
In simple terms: Long non-coding RNAs can produce small proteins that push fibroblasts into an activated state.
LINC01013 is a determinant of fibroblast activation and encodes a novel fibroblast-activating micropeptide. This finding expands the regulatory layer of GO:0072537 beyond classical protein-coding signaling, showing that a long non-coding RNA can directly contribute to the activated phenotype through a translated micropeptide. Such non-coding regulators may explain context-specific activation states that are not captured by canonical cytokine pathways alone.
Phenoconversion and fibrosis
In simple terms: Sustained activation can convert fibroblasts into matrix-producing cells that drive fibrosis.
In the heart, signaling mechanisms regulating fibroblast activation, phenoconversion, and fibrosis have been reviewed as a continuum in which activated fibroblasts acquire a myofibroblast-like phenotype and deposit excess matrix. This phenoconversion is a clinically relevant outcome of GO:0072537 because it underlies cardiac fibrosis and adverse remodeling. Similar principles apply in lung fibrosis, where YAP/TAZ-dependent mechanosignaling sustains activation. Thus, the biological process of fibroblast activation can progress to persistent fibrosis when activating signals are not resolved.
Resolution and tissue remodeling
In simple terms: Activation can be temporary and help tissue remodel rather than scar.
Fibroblast activation is not always pathological. Resistance training rejuvenates aging skin by reducing circulating inflammatory factors and enhancing dermal extracellular matrices, indicating that fibroblast behavior can be modulated toward beneficial remodeling. In the dental pulp, pulp fibroblasts contribute to the local control of pulp inflammation via complement activation, showing that fibroblast activation can participate in inflammatory control rather than only in fibrosis. These contexts illustrate that the outcome of GO:0072537 depends on the duration and nature of the activating factor.
Key Genes Involved in GO:0072537 fibroblast activation
The following genes and proteins have been experimentally implicated in fibroblast activation (GO:0072537) in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| YAP1 | Mechanosignaling effector that drives fibroblast activation and fibrosis | Central to linking mechanical cues to activation |
| WWTR1 (TAZ) | Mechanosignaling effector cooperating with YAP | Drives fibroblast activation and fibrosis |
| FAP | Promotes immunosuppression by cancer-associated fibroblasts via STAT3-CCL2 signaling | Therapeutic target in tumor microenvironment |
| STAT3 | Transcription factor mediating FAP-driven CCL2 signaling | Links fibroblast activation to immune suppression |
| CCL2 | Chemokine downstream of STAT3 in cancer-associated fibroblasts | Mediates immunosuppression in tumors |
| LINC01013 | Long non-coding RNA determinant of fibroblast activation encoding a micropeptide | Non-coding regulator of activation |
| PU.1/Spi1 | Transcription factor exacerbating ischemia-reperfusion acute kidney injury | Upregulates Gata2 and promotes fibroblast activation |
| GATA2 | Transcription factor downstream of PU.1/Spi1 in kidney injury | Promotes fibroblast activation in acute kidney injury |
| FAP (periodontal) | Enzymatic activity essential for TGF-beta1-induced fibroblastic differentiation | Required for periodontal ligament cell differentiation |
| TGFB1 | Soluble ligand that induces fibroblastic differentiation | Activating factor for periodontal ligament cells |
| Complement components | Participate in pulp fibroblast control of pulp inflammation | Local inflammatory control in dental pulp |
| Cardiac fibroblast signaling mediators | Regulate activation, phenoconversion, and fibrosis in the heart | Cardiac fibrosis mechanisms |
| Dermal extracellular matrix genes | Enhance dermal extracellular matrices after resistance training | Skin rejuvenation and remodeling |
| Inflammatory factors (circulating) | Reduced by resistance training in aging skin | Modulate fibroblast behavior in skin |
How Is fibroblast activation Regulated?
Fibroblast activation (GO:0072537) is regulated at multiple levels. Mechanistically, YAP and TAZ transduce mechanical signals into transcriptional programs that drive activation and fibrosis, making them key upstream regulators. Soluble ligands such as TGF-beta1 regulate activation in periodontal ligament cells, and this process requires the enzymatic activity of fibroblast activation protein-alpha. In cancer-associated fibroblasts, STAT3-CCL2 signaling downstream of FAP regulates the immunosuppressive program associated with activation. Transcriptional control is also important: PU.1/Spi1 upregulates Gata2 to promote fibroblast activation in ischemia-reperfusion acute kidney injury. Non-coding regulation occurs through LINC01013, which encodes a fibroblast-activating micropeptide. In the heart, signaling mechanisms regulating fibroblast activation, phenoconversion, and fibrosis have been reviewed as an integrated regulatory network. Finally, systemic factors can modulate fibroblast behavior, as resistance training reduces circulating inflammatory factors and enhances dermal extracellular matrices in aging skin. Together, these studies indicate that fibroblast activation is controlled by mechanotransduction, cytokine signaling, transcription factors, non-coding RNAs, and systemic inflammatory status.
fibroblast activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| YAP1 / WWTR1 | Lung fibrosis via mechanosignaling | Knockout or overexpression in lung fibroblasts |
| FAP | Cancer-associated fibroblast immunosuppression | Knockout in cancer-associated fibroblasts followed by STAT3-CCL2 readout |
| PU.1/Spi1 | Ischemia-reperfusion acute kidney injury | Knockout or overexpression in kidney injury models |
| GATA2 | Acute kidney injury downstream of PU.1/Spi1 | Knock-in or knockout to test Gata2 dependence |
| FAP (periodontal) | TGF-beta1-induced periodontal ligament differentiation | Point mutation of enzymatic activity in periodontal ligament cells |
Fibroblast activation in fibrosis and organ injury
Fibroblast activation is a central mechanism of fibrosis in multiple organs. In the lung, mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis, linking mechanical stress to pathological matrix deposition. In the heart, signaling mechanisms regulating fibroblast activation, phenoconversion, and fibrosis contribute to cardiac remodeling and heart failure. In the kidney, PU.1/Spi1 exacerbates ischemia-reperfusion induced acute kidney injury via upregulating Gata2 and promoting fibroblast activation, identifying a transcriptional axis that could be targeted. In the periodontal ligament, TGF-beta1-induced fibroblastic differentiation requires FAP enzymatic activity, connecting activation to dental tissue pathology. These examples demonstrate that GO:0072537 is a shared pathogenic process across diverse organs.
Fibroblast activation in cancer
In the tumor microenvironment, fibroblast activation underlies the cancer-associated fibroblast phenotype. FAP promotes immunosuppression by cancer-associated fibroblasts via STAT3-CCL2 signaling, providing a direct link between fibroblast activation and immune evasion. Because FAP is a marker of activated fibroblasts, this study supports the concept that GO:0072537 contributes to tumor progression by shaping the immune microenvironment. Targeting fibroblast activation pathways may therefore complement immunotherapies, although the verified literature here focuses on the mechanistic role of FAP-STAT3-CCL2 signaling.
Fibroblast activation in inflammation and tissue remodeling
Fibroblast activation also participates in inflammatory control and tissue remodeling. In the dental pulp, pulp fibroblasts contribute to the local control of pulp inflammation via complement activation, indicating that activated fibroblasts can modulate inflammatory responses. In aging skin, resistance training rejuvenates the dermis by reducing circulating inflammatory factors and enhancing dermal extracellular matrices, a process in which fibroblast behavior is central. These findings suggest that fibroblast activation can be beneficial or detrimental depending on context, and that systemic interventions can influence the process.
Non-coding RNA contributions to fibroblast activation in disease
LINC01013 is a determinant of fibroblast activation and encodes a novel fibroblast-activating micropeptide, expanding the disease-relevant regulatory landscape of GO:0072537. Although the verified literature does not specify a single disease for LINC01013, its identification as a fibroblast-activating factor suggests that non-coding RNAs may contribute to fibrotic or remodeling diseases. This highlights the importance of including non-coding regulators in functional screens of fibroblast activation.
From fibroblast activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is YAP/TAZ required for fibroblast activation? | YAP1 or WWTR1 knockout fibroblasts |
| Does FAP enzymatic activity drive TGF-beta1-induced differentiation? | Point mutation of FAP catalytic residues in periodontal ligament cells |
| Does PU.1/Spi1 upregulate Gata2 to promote activation? | Knockout or knock-in of PU.1/Spi1 binding sites |
| Does LINC01013-encoded micropeptide activate fibroblasts? | Overexpression or knockout of LINC01013 |
| Can FAP-STAT3-CCL2 signaling be disrupted? | STAT3 knockout or CCL2 knock-in reporter in cancer-associated fibroblasts |
| Does GATA2 mediate kidney fibroblast activation? | Gata2 knockout or overexpression in kidney injury models |
How to Study the fibroblast activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes during activation | Identify activation-associated gene programs |
| Western blot | Protein levels and phosphorylation | Measure STAT3 phosphorylation and FAP expression |
| Immunofluorescence | Morphology and protein localization | Assess YAP/TAZ nuclear translocation |
| Enzymatic activity assay | FAP catalytic activity | Test requirement for TGF-beta1-induced differentiation |
| CRISPR knockout | Loss-of-function causality | Test YAP1, WWTR1, or PU.1/Spi1 requirement |
| CRISPR point mutation | Specific residue function | Separate FAP enzymatic activity from other functions |
| Overexpression | Gain-of-function sufficiency | Test LINC01013 micropeptide sufficiency |
| In vivo injury models | Disease outcome | Ischemia-reperfusion kidney injury and lung fibrosis |
Transcriptional and signaling assays
Researchers studying fibroblast activation (GO:0072537) commonly measure transcriptional readouts of activation, such as YAP/TAZ target genes, after mechanical or ligand stimulation. In cancer-associated fibroblasts, STAT3-CCL2 signaling can be assessed by measuring CCL2 expression and STAT3 phosphorylation following FAP manipulation. In periodontal ligament cells, TGF-beta1-induced differentiation can be monitored with fibroblastic markers and FAP enzymatic activity assays. These methods establish whether a candidate gene or ligand changes the activation state of fibroblasts.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression are used to test causality in fibroblast activation. For example, knocking out YAP1 or WWTR1 can determine whether mechanosignaling is required for activation and fibrosis. Point mutations in FAP can separate enzymatic activity from scaffolding functions in TGF-beta1-induced differentiation. Knock-in of reporter or tagged alleles enables tracking of activation-associated proteins in live cells. Overexpression of LINC01013 or its encoded micropeptide can test sufficiency for activation.
In vivo disease models
In vivo models are essential to link fibroblast activation to disease. Ischemia-reperfusion acute kidney injury models have been used to show that PU.1/Spi1 upregulates Gata2 and promotes fibroblast activation. Lung fibrosis models have demonstrated that YAP/TAZ mechanosignaling drives fibroblast activation and fibrosis. Cardiac fibrosis models have been used to study signaling mechanisms regulating fibroblast activation, phenoconversion, and fibrosis. These models allow researchers to test whether genetic perturbations alter disease outcomes.
Non-coding RNA and micropeptide analysis
Because LINC01013 encodes a fibroblast-activating micropeptide, studying GO:0072537 now includes non-coding RNA analysis. Methods include RNA sequencing to detect LINC01013 expression, ribosome profiling to confirm micropeptide translation, and overexpression or knockout to test function. These approaches complement classical protein-coding screens and can reveal hidden regulators of fibroblast activation.
How CRISPR Can Be Used to Study GO:0072537 fibroblast activation
Knockout
CRISPR knockout is used to test whether a gene is required for fibroblast activation. For example, knocking out YAP1 or WWTR1 can determine whether mechanosignaling through YAP and TAZ is necessary for fibroblast activation and fibrosis. Knocking out PU.1/Spi1 or Gata2 can test their roles in ischemia-reperfusion acute kidney injury and fibroblast activation. Knockout of FAP or STAT3 can assess the FAP-STAT3-CCL2 axis in cancer-associated fibroblasts. These loss-of-function experiments provide causal evidence for GO:0072537 regulators.
Point Mutation
CRISPR point mutation enables precise testing of catalytic or post-translational regulatory residues. The enzymatic activity of fibroblast activation protein-alpha is essential for TGF-beta1-induced fibroblastic differentiation of human periodontal ligament cells, so point mutations that abolish FAP catalytic activity can separate enzymatic function from other roles. Point mutations can also be used to disrupt phosphorylation sites in signaling mediators such as STAT3, although the verified literature here focuses on FAP. This approach is valuable when a gene has multiple domains or activities.
Knock-in
CRISPR knock-in can introduce reporters, tags, or disease-relevant alleles. For example, knock-in of a fluorescent reporter at the Gata2 locus could track its expression during kidney fibroblast activation downstream of PU.1/Spi1. Tagged knock-in of YAP1 or WWTR1 could enable live-cell imaging of nuclear translocation during mechanosignaling. Knock-in of a micropeptide tag at the LINC01013 locus could confirm translation of the fibroblast-activating micropeptide. These models provide spatial and temporal resolution of fibroblast activation.
Overexpression
CRISPR overexpression, often via CRISPR activation or targeted integration, tests sufficiency of a candidate gene for fibroblast activation. Overexpression of LINC01013 or its encoded micropeptide can determine whether it is sufficient to activate fibroblasts. Overexpression of PU.1/Spi1 or Gata2 can test whether these transcription factors drive activation in kidney or other cell contexts. Overexpression of FAP or STAT3 can test whether the FAP-STAT3-CCL2 axis is sufficient to induce immunosuppressive programs in cancer-associated fibroblasts. These gain-of-function experiments complement knockout studies.
How EDITGENE Supports fibroblast activation Research
Researchers studying fibroblast activation-related genes often need to determine whether a candidate gene is causally involved in the morphological and behavioral changes that define GO:0072537. This requires precise genetic models that can distinguish necessity from sufficiency and can separate enzymatic activity from scaffolding functions. EDITGENE provides a comprehensive suite of CRISPR services tailored to fibroblast activation research, from knockout to point mutation, knock-in, overexpression, library screening, and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for fibroblast activation research.
Frequently Asked Questions About fibroblast activation
What is fibroblast activation (GO:0072537)?
Fibroblast activation (GO:0072537) is a biological process defined as a change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand.
What genes are involved in fibroblast activation?
Key genes include YAP1 and WWTR1 (TAZ) in mechanosignaling, FAP, STAT3, and CCL2 in cancer-associated fibroblasts, PU.1/Spi1 and GATA2 in kidney injury, and LINC01013 encoding a fibroblast-activating micropeptide.
How is fibroblast activation regulated?
It is regulated by mechanosignaling through YAP and TAZ, soluble ligands such as TGF-beta1, transcriptional regulators such as PU.1/Spi1 and GATA2, non-coding RNAs such as LINC01013, and systemic inflammatory factors.
What diseases involve fibroblast activation?
Fibroblast activation is involved in lung fibrosis, cardiac fibrosis, ischemia-reperfusion acute kidney injury, periodontal ligament differentiation, cancer-associated fibroblast immunosuppression, and pulp inflammation.
What is the role of FAP in fibroblast activation?
FAP promotes immunosuppression by cancer-associated fibroblasts via STAT3-CCL2 signaling, and its enzymatic activity is essential for TGF-beta1-induced fibroblastic differentiation of human periodontal ligament cells.
How do YAP and TAZ drive fibroblast activation?
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis by converting mechanical cues into transcriptional programs.
What is LINC01013 and how does it affect fibroblasts?
LINC01013 is a long non-coding RNA that is a determinant of fibroblast activation and encodes a novel fibroblast-activating micropeptide.
How can CRISPR be used to study fibroblast activation?
CRISPR knockout, point mutation, knock-in, and overexpression can test necessity and sufficiency of genes such as YAP1, WWTR1, FAP, PU.1/Spi1, GATA2, and LINC01013 in fibroblast activation.
What experimental models are used for fibroblast activation research?
Models include lung fibrosis and mechanosignaling assays, ischemia-reperfusion acute kidney injury models, periodontal ligament cell differentiation assays, and cancer-associated fibroblast co-culture systems.
Why is fibroblast activation important for cancer?
Fibroblast activation underlies the cancer-associated fibroblast phenotype, and FAP-positive fibroblasts promote immunosuppression via STAT3-CCL2 signaling in the tumor microenvironment.
Conclusion
Fibroblast activation (GO:0072537) is a broadly relevant biological process defined by changes in fibroblast morphology or behavior in response to activating factors such as cellular or soluble ligands. The verified literature shows that this process is driven by mechanosignaling through YAP and TAZ, soluble ligands such as TGF-beta1, transcriptional regulators including PU.1/Spi1 and GATA2, and non-coding regulators such as LINC01013. It is central to fibrosis in the lung, heart, and kidney, to cancer-associated fibroblast immunosuppression, and to dental and skin remodeling. CRISPR-based knockout, point mutation, knock-in, and overexpression models provide the causal toolkit needed to dissect these mechanisms. EDITGENE supports this research with end-to-end CRISPR services and bioinformatics.
References
- 1. Liu F et al.. 2015. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.. Am J Physiol Lung Cell Mol Physiol 308(4):L344-57 PMID: 25502501
- 2. Le Fournis C et al.. 2020. Pulp Fibroblast Contribution to the Local Control of Pulp Inflammation via Complement Activation.. J Endod 46(9S):S26-S32 PMID: 32950192
- 3. MacLean J et al.. 2014. Signaling mechanisms regulating fibroblast activation, phenoconversion and fibrosis in the heart.. Indian J Biochem Biophys 51(6):476-82 PMID: 25823219
- 4. Yang X et al.. 2016. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.. Cancer Res 76(14):4124-35 PMID: 27216177
- 5. Quaife NM et al.. 2023. LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide.. J Cardiovasc Transl Res 16(1):77-85 PMID: 35759180
- 6. Zong C et al.. 2025. PU.1/Spi1 exacerbates ischemia-reperfusion induced acute kidney injury via upregulating Gata2 and promoting fibroblast activation.. Acta Pharmacol Sin 46(8):2251-2266 PMID: 40169783
- 7. Nishikori S et al.. 2023. Resistance training rejuvenates aging skin by reducing circulating inflammatory factors and enhancing dermal extracellular matrices.. Sci Rep 13(1):10214 PMID: 37353523
- 8. Kim SM et al.. 2024. Enzymatic activity of fibroblast activation protein-α is essential for TGF-β1-induced fibroblastic differentiation of human periodontal ligament cells.. Exp Cell Res 442(2):114230 PMID: 39222867
